ENTITY
BeiGene

BeiGene (BGNE US)

131
Analysis
Health CareChina
BeiGene, Ltd. operates as a commercial stage biopharmaceutical company. The Company focuses on discovery, development, and commercialization of molecularly targeted and immuno-oncology drugs for the treatment of cancer. BeiGene serves patients worldwide.
more
Refresh
27 Aug 2018 06:05

Last Week in GER Research: Haidilao, Xiaomi, Ping An, 111, Qutoutiao, Nio and Tesla

Below is a recap of the key IPO and fundamental research produced by the Global Equity Research team. This week we highlight a differentiated...

Logo
352 Views
Share
bearishTesla
13 Aug 2018 04:27

Last Week in GER Research: Tesla, Pinduoduo, Beigene, Koolearn, Pintec, STX and China Tower

Below is a recap of the key research produced by the Global Equity Research team. This week we highlight some detailed math on a potential Tesla...

Logo
323 Views
Share
bullishBeiGene
13 Aug 2018 03:52

BeiGene (6160 HK): On a Stronger Post-Listing Footing than Ascletis

Hong Kong investors have had their first taste of biotech stocks with the recent listings of Ascletis Pharma Inc (1672 HK) and BeiGene Ltd (6160...

Logo
396 Views
Share
bullishBeiGene
08 Aug 2018 10:39

BeiGene (百济神州) Post-IPO: An ADR Tracker with Limited Near-Term Upside

BeiGene is the second biotech company to list in Hong Kong under amended listing rules that allow biotech companies which are yet to see a profit...

Logo
398 Views
Share
bearishChina Tower
06 Aug 2018 04:50

Last Week in GER Research: Ascletis Pharma, China Tower, Pinduoduo, Beigene and CNFinance

Below is a recap of the key IPO research produced by the Global Equity Research team. This week we highlight our sensitivity analysis for Ascletis...

Logo
795 Views
Share
x